fibromyalgia

People who live with the pain, nausea, anxiety, depression and other symptoms of fibromyalgia also live with the sad fact that there’s no cure and not a single drug to treat this condition that affects 3% to 5% of the world's population and 3.5 million people in ...

Following an unblinded, pre-planned interim analysis by the Independent Data Monitoring Committee (IDMC), Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) will stop enrollment in the Phase 3 RALLY study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for fibromyalgia. The...

NeuroMetrix Inc's (NASDAQ: NURO) Quell device has received Breakthrough Designation from the FDA to treat fibromyalgia symptoms in adults. Fibromyalgia is a common form of chronic pain accompanied by fatigue, sleep, cognitive and mood disturbances.  Quell is a wearable...

After a pre-NDA meeting with FDA, Axsome Therapeutics Inc (NASDAQ: AXSM) has announced its plan to submit a marketing application seeking approval for AXS-14 to manage fibromyalgia. The submission is currently anticipated in the fourth quarter of 2022, pending completion of...

Virios Therapeutics Inc (NASDAQ: VIRI) has announced that data from its Phase 2a PRID-201 trial demonstrated that IMC-1 was better tolerated than placebo in patients with fibromyalgia. The disease is characterized by widespread musculoskeletal pain accompanied by fatigue, sleep,...

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has announced the poster presentation of previously reported results from its Phase 3 RELIEF trial evaluating the TNX-102 SL tablet for the management of fibromyalgia. Fibromyalgia is a disorder characterized by widespread...

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are gaining momentum following a Thursday morning announcement from the company.  What Happened Tonix, a biopharma company developing treatments for serious neuropsychiatric and central nervous system conditions, said it plans to...

Despite confirming third-quarter catalysts and progress throughout its development pipeline, Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE)’s first-quarter financial report didn’t impress investors. The company conceded an 8.3-percent stock decline Tuesday even as it boasts a 22-percent...

In a report published Friday, Oppenheimer analyst Akiva Felt initiated coverage of Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) with an Outperform rating and a price target of $18. Analyst Akiva Felt believes that Tonix has been "overlooked" by investors after mixed Phase 2...